Epidermal growth factor receptor (EGFR) activating mutations occur in approximately 50% of East Asian patients with non-small-cell lung cancer (NSCLC) and confer sensitivity to tyrosine kinase inhibitors (TKIs). ASP8273 is an irreversible EGFR-TKI, given orally, that inhibits EGFR activating mutations and has shown clinical activity in patients with EGFR mutation-positive NSCLC. Epidermal growth factor receptor-TKI-na€ ıve Japanese adult patients (≥20 years) with NSCLC harboring EGFR mutations were enrolled in this open-label, single-arm, phase II study (ClinicalTrials.gov identifier NCT02500927). Patients received ASP8273 300 mg once daily until discontinuation criteria were met. The primary end-point was to determine the safety of ASP8273 300 mg; the secondary end-point was antitumor activity defined by RECIST version 1.1. Thirty-one patients (12 men and 19 women; median age, 64 years [range, 31-82 years]) with EGFR mutation-positive NSCLC were enrolled; as of 23 February 2016, 25 patients (81%) were still on study. Of the 31 patients, 27 (87%) had an exon 19 deletion (n = 13, 42%) or an L858R (n = 14, 45%) EGFR activating mutation, and two (7%) had an L861Q mutation. Five patients (16%) had other EGFR activating mutations, two had an activating mutation and the T790M resistance mutation. The most commonly reported treatment-emergent adverse event was diarrhea (n = 24, 77%). All patients had at least one post-baseline scan; one patient (3%) achieved a confirmed complete response, 13 (42%) had a confirmed partial response, and 15 (48%) had confirmed stable disease (disease control rate, 94% [n = 29/31]) per
| INTRODUCTION
Epidermal growth factor receptor mutations are estimated to be present in approximately 50% of NSCLC patients in East Asian countries. 1 The presence of EGFR activating mutations in NSCLC patients can result in increased malignant cell survival, proliferation, invasion, metastatic spread, and tumor angiogenesis. 2, 3 The most common EGFR mutations are exon 19 deletions and exon 21 L858R substitutions. 2, 4 These mutations confer sensitivity to TKIs and account for approximately 90% of EGFR mutations seen in patients with NSCLC. 5 The presence of EGFR activating mutations in NSCLC patients is an important predictor of response and outcome to treatment with EGFR-TKIs and patients with these mutations have experienced antitumor activity and prolonged PFS following treatment with the reversible EGFR-TKIs gefitinib and erlotinib. 6, 7 Clinical efficacy, however, is often limited by an acquired drug resistance, most commonly caused by a point mutation (T790M) in the gene encoding EGFR.
Approximately 50%-60% of patients treated with TKIs develop T790M-mediated resistance, suggesting that, along with activating mutations, the T790M mutation is an important factor in determining the appropriate treatment strategy in these patients. 8, 9 ASP8273 is an oral irreversible EGFR-TKI that inhibits the kinase activity of EGFR containing the ex19del or L858R activating mutation and the T790M resistance mutation. In preclinical studies, ASP8273 inhibited the kinase activity of EGFR-containing activating mutations, ex19del, and exon 21 L858R. ASP8273 also inhibited the kinase activity of EGFR containing both an activating mutation and the T790M resistance mutation (ie ex19del/T790M and T790M/ L858R). ASP8273 inhibited EGFR phosphorylation in NCI-H1975 cells and maintained inhibition for 24 hours after washout. ASP8273
is a third-generation EGFR-TKI that inhibits T790M mutant EGFR selectively with less activity against WT EGFR than second-generation EGFR-TKIs (gefitinib and erlotinib 
| MATERIALS AND METHODS

| Study design and treatment
This open-label, single-arm, phase II study (NCT02500927) was undertaken at 11 medical centers in Japan. Eligible patients were aged ≥20 years, EGFR-TKI treatment-na€ ıve with a histologically or cytologically confirmed diagnosis of stage IIIB/IV NSCLC, and a documented activating EGFR mutation (ex19del, L858R, G719X, or L861Q 
| Procedures
Target and non-target tumor lesions were assessed by the investigator using RECIST version 1. L861Q, S768I, G719A, G719S, G719C, and exon 20 insertion mutation) and for the EGFR-T790M mutation were also analyzed.
| Statistical analysis
All patients who received at least one dose of ASP8273, who had acceptable images for baseline tumor assessment, and who were evaluated for at least one efficacy end-point after start of treatment were included in the full analysis set. Patients who received at least one dose of ASP8273 were included in the safety analysis set.
The frequency and percentage of AEs by subcategories including relation to study drug, severity, and events leading to study drug interruption were summarized. Quantitative and qualitative laboratory values were summarized at each visit; laboratory results were classified as low, normal, or high and shifts from baseline were noted.
The antitumor effect of ASP8273 was assessed based on RECIST version 1.1. The ORR was defined as the proportion of patients whose best overall response over the entire exposure period was rated as CR or PR. The DCR, which was defined as the proportion of patients whose best overall response over the entire exposure period was rated as CR, PR, or SD, was calculated. The median follow-up time for PFS was estimated according to the Kaplan-Meier estimate of potential follow-up.
| RESULTS
| Disposition, demographics, and disease characteristics
Thirty-three patients provided informed consent and were screened for the study; two patients failed inclusion or exclusion criteria as described in the trial profile ( Figure 1 ).
A total of 31 Japanese patients (12 men and 19 women; median age, 64 years [range, 31-82 years]) were enrolled from 11 centers in Japan (Table 1) . Based on local testing, 27 patients had either an ex19del (n = 13, 42%) or an L858R (n = 14, 45%) EGFR activating mutation, two patients had L861Q mutation (7%) and five patients (16%) had other EGFR activating mutations. Some samples were The median duration of exposure was 112 days for 300 mg and 139 days for all doses (including dose decreased to 200 or 100 mg).
Dose reduction was experienced by 23% (n = 7/31) of patients and dose interruption by 55% (n = 17/31) of patients; all dose reductions were due to an AE. Dose interruption due to an AE was experienced by 42% (n = 13/31) of patients and dose interruption due to other reasons was experienced by 29% (n = 9/31) of patients. The median duration of interruption was 1 day (range, 0 to 42 days) for all dose levels.
| Safety
ASP8273 at 300 mg had a tolerable toxicity profile, with diarrhea and peripheral neuropathy being common TEAEs. All 31 (100%)
patients reported ≥1 treatment-related AE during the study (Table 2) , the most common of which were diarrhea (68%, n = 21), peripheral sensory neuropathy (39%, n = 12), alanine aminotransferase increased (36%, n = 11), and nausea. No deaths were reported during the study; serious TEAEs considered related to ASP8273 were reported in 10% (n = 3/31) of patients and included hepatotoxicity, increased ALT, increased AST, and dehydration. There were no TEAEs leading to permanent discontinuation of study drug. Treatment-related TEAEs leading to drug interruption, including anemia, sinus bradycardia, nausea, vomiting, fatigue, malaise, pyrexia, hepatotoxicity, increased ALT, increased AST, decreased neutrophils, decreased appetite, dehydration, hyponatremia, renal impairment, and epistaxis were reported in 36% (n = 11/31) of patients. Treatment-emergent AEs of special interest were hyperglycemia (n = 1, 3%), prolonged QT interval on electroencephalogram (n = 1, 3%), and interstitial lung disease-like events (n = 0).
Potentially clinically significant values in liver enzymes were reported, including increased alkaline phosphatase >1.5 9 ULN (n = 7), increased ALT or AST >3 9 ULN (n = 6), increased ALT >5 9 ULN (n = 3) and increased AST >5 9 ULN (n = 1), and increased ALT >10 9 ULN (n = 1). There was no patient with ALT and/or AST >3 9 ULN and total bilirubin >2 9 ULN. Baseline ECOG performance status was grade 1 for 42% (n = 13/31) of patients.
Three patients had a maximum post-baseline ECOG performance status of grade 2; however, no ECOG performance status score was grade ≥3 in severity.
| Antitumor activity
In total, 30 of the 31 patients had evaluable target lesion data. As detailed in Table 3 and Figure 2 (A), one patient experienced a CR, 13 achieved PR, 15 achieved SD, and one had progressive disease.
The ORR (defined as CR + PR) was 45% (n = 14/31; 95% CI, 27.3-64.0), and the DCR was 94% (n = 29/31; 95% CI, 78.6-99.2) for derived ASP8273 response assessments with confirmation. The PFS rate at 6 months was 86% (95% CI, 67-94). The median duration of PFS could not be estimated, as 81% (25/31) of patients were ongoing without death or progressive disease after more than 105 days, and had not received new anticancer therapy. Among patients with ex19del (n = 13), ASP8273 was associated with an ORR of 31% (95% CI, 9.1-61.4) and DCR of 85% (95% CI, 55-98). In patients with the L858R mutation (n = 14), ASP8273 300 mg was associated with an ORR of 57% (95% CI, 29-82) and DCR of 100% (95% CI, T A B L E 2 Treatment-related adverse events occurring in ≥5% of the total population Japanese patients with EGFR mutation-positive non-small-cell lung cancer, n (%) ASP8273 300 mg (n = 31) Abdominal discomfort 2
Oral dysesthesia 2
Oral pain 2 (7)
Blood alkaline phosphatase increased 2 (7)
Protein total increased 2 (7) Dysesthesia 2
Peripheral neuropathy 2 (7) Paresthesia 2
Urinary retention 2
Dermatitis acneiform 2
Pruritis 2 (7) 77-100). Although PFS could not be estimated at the data cut-off of patients, and patients with L858R mutation were 11.3 months (range, 0.7-15.5; Figure 2B ), 8.3 months (range, 0.72-12.55; Figure 2C ), and 15.5 months (range 1.38-15.51; Figure 2D ), respectively. F I G U R E 2 Antitumor activity in tyrosine kinase inhibitor-na€ ıve Japanese patients with EGFR mutation-positive non-small-cell lung cancer treated with ASP8273. A, Best percent change from baseline in target-lesion size. B, Progression-free survival of all subjects receiving ASP8273. C, Progression-free survival of patients with exon 19 deletion (ex19del)-positive mutation. D, Progression-free survival of patients with L858R mutation comparing gefitinib with chemotherapy for the treatment of NSCLC with mutated EGFR, one patient out of 114 who received gefitinib experienced sensory neuropathy, and 62 of 113 (55%) patients who received chemotherapy experienced sensory neuropathy. 10 Instances of peripheral sensory neuropathy were of low severity (grade ≤2, n = 12; grade ≥3, n = 0), and patients who experienced hyponatremia (grade ≤2, n = 3; grade ≥3, n = 7) were able to continue treatment with ASP8273 as the condition resolved. Across the study, no patient reported interstitial lung disease, a common occurrence among patients with NSCLC. Although potentially clinically significant values in liver enzymes and total bilirubin were noted, there was no patient with ALT and/or AST >3 9 ULN and total bilirubin >2 9 ULN. One patient in the study had an ALT value >10 9 ULN. This safety/tolerability profile was similar to that observed with ASP8273 in the first-in-human study (NCT02192697), carried out in Asia, which enrolled patients who had progressed on a prior EGFR-TKI (phase I) and who were T790M-positive (phase II).
| DISCUSSION
EGFR T790M-mediated resistance to EGFR-TKIs is a dominant resistance mechanism. In this study, subjects harboring the L858R activating mutation showed higher efficacy than those with ex19del, although the study cohort was very limited. Additionally, two of the 31 enrolled patients (6%) presented with T790M prior to treatment.
The T790M mutation has been considered a rare phenomenon prior to exposure to EGFR-TKIs, however, in a meta-analysis that included was supported by decreased circulating EGFR T790M cell-free DNA to below the level of detection, confirming successful on-target inhibition. 13 Together, these results reveal that ASP8273 has antitumor activity and was tolerated well by patients with advanced disease. Generally, these ASP8273 clinical data provide further insight into achieving the optimal antitumor effects of third-generation EGFRTKIs when used as first-line treatment for patients with EGFR activating mutations L858R and ex19del.
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